Blocking ADP-ribosylation expands the anti-mycobacterial spectrum of rifamycins

The clinical utility of rifamycins against non-tuberculous mycobacterial (NTM) disease is limited by intrinsic drug resistance achieved by ADP-ribosyltransferase Arr. By blocking the site of ribosylation, we recently optimized a series of analogs with substantially improved potency against Mycobacte...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganapathy, Uday S., Lan, Tian, Dartois, Véronique, Aldrich, Courtney C., Dick, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580999/
https://www.ncbi.nlm.nih.gov/pubmed/37681986
http://dx.doi.org/10.1128/spectrum.01900-23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580999/
https://www.ncbi.nlm.nih.gov/pubmed/37681986
http://dx.doi.org/10.1128/spectrum.01900-23

Ejemplares similares